1. Understand scope and potential impact of cardiorenal and metabolic risk mitigation in type 2 diabetes.
2. Review evidence on the role of GLP-1 receptor agonists and SGLT2 inhibitors in improving cardiovascular and renal outcomes.
3. Review updates in guidelines pertaining to use of diabetes therapeutic agents for cardiorenal risk reduction.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation